Frontier Pharma: Women's Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline

  • ID: 4473079
  • Report
  • Region: Global
  • 86 Pages
  • GBI Research
1 of 4

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

Despite this, the women’s health market is relatively small. This reflects diagnostic barriers and high levels of non-treatment for women’s health disorders, as well as high levels of genericization and relatively limited innovation within recent decades.

Consequently, there is strong rationale for continued R&D investment in women’s health therapeutics due to high levels of unmet need across many indications.

This report assesses first-in-class innovation across the women’s health therapy area, with a particular focus on three key indications: endometriosis, polycystic ovarian syndrome (PCOS) and cervical intraepithelial neoplasia (CIN).

Scope

  • Many women’s health disorders are highly prevalent. How do epidemiology trends vary for endometriosis, PCOS and CIN?
  • Innovation within women’s health has been relatively limited over recent decades. What are the most prominent unmet needs across this therapy area?
  • There are 261 pipeline programs in active development for women’s health. What proportion of these products are first-in-class? How does first-in-class innovation vary by indication, development stage and molecular target class?
  • Although the first-in-class pipeline is relatively modest in size it is considerably diverse with eight distinct molecular target classes represented. Which first-in-class targets have been identified as most promising for women’s health conditions?
  • Over 200 licensing deals relating to women’s health have been completed since 2006. Do women’s health products typically attract high deal values? Which first-in-class products have prior deal involvement?

Reasons to buy

  • Understand the current clinical and commercial landscape. This includes a comprehensive study of symptoms, epidemiology, etiology, pathophysiology, co-morbidities and complications, diagnosis and treatment options.
  • Visualize the composition of the women’s health market in terms of dominant molecule types and molecular targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
  • Analyze the women’s health pipeline and stratify by stage of development, molecule type and molecular target.
  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
  • Recognize commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals, and identifying women’s health therapies that have not yet been involved in deals and may offer potential investment opportunities.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

1 Table of Contents

2 Executive Summary
2.1 Expanding Pipeline Has Potential to Address Unmet Needs of Large Prevalence Population
2.2 First-in-Class Innovation Concentrated Across Endometriosis, Polycystic Ovarian Syndrome and Cervical Intraepithelial Neoplasia
2.3 Despite High Licensing Deal Activity, Most First-in-Class Products Have No Prior Deal Involvement

3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation in Women’s Health
3.6 Research Report Guidance

4 Clinical and Commercial Landscape
4.1 Therapy Area Overview
4.2 Disease Overview and Symptoms
4.2.1 Endometriosis
4.2.2 Polycystic Ovarian Syndrome
4.2.3 Cervical Intraepithelial Neoplasia
4.3 Diagnosis
4.3.1 Endometriosis
4.3.2 Polycystic Ovarian Syndrome
4.3.3 Cervical Intraepithelial Neoplasia
4.4 Epidemiology and Etiology
4.4.1 Endometriosis
4.4.2 Polycystic Ovarian Syndrome
4.4.3 Cervical Intraepithelial Neoplasia
4.5 Pathophysiology
4.5.1 Endometriosis
4.5.2 Polycystic Ovarian Syndrome
4.5.3 Cervical Intraepithelial Neoplasia
4.6 Co-morbidities and Complications
4.6.1 Endometriosis
4.6.2 Polycystic Ovarian Syndrome
4.6.3 Cervical Intraepithelial Neoplasia
4.7 Treatment
4.7.1 Treatment Options
4.7.2 Treatment Algorithms
4.8 Overview of Marketed Products within Women’s Health

5 Pipeline Assessment
5.1 Overview
5.2 Pipeline by Stage of Development and Molecule Type
5.3 Pipeline by Molecular Target
5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class
5.5 First-in-Class Programs Targeting Novel Molecular Targets
5.6 Ratio of First-in-Class Products to First-in-Class Targets
5.7 List of All Pipeline Products

6 Signalling Network, Disease Causation and Innovation Alignment
6.1 Complexity of Signaling Networks
6.2 Signaling Pathways and First-in-Class Molecular Target Integration
6.3 First-in-Class Matrix Assessments

7 First-in-Class Target Evaluation
7.1 First-in-Class Programs Targeting Prostaglandin E2 Receptor EP4 Subtype (PTGER4) for Endometriosis
7.2 First-in-Class Programs Targeting Patatin-Like Phospholipase Domain Containing Protein 2 (PNPLA2) for Endometriosis, PCOS and Ovarian Hyperstimulation Syndrome
7.3 First-in-Class Programs Targeting Glutamyl Aminopeptidase (ENPEP) for Endometriosis
7.4 First-in-Class Programs Targeting Prostaglandin E Synthase (PTGES) for Endometriosis
7.5 First-in-Class Programs Targeting Kiss 1 Receptor (KISS1R) for Endometriosis, PCOS and Infertility
7.6 First-in-Class Programs Targeting Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for Endometriosis
7.7 First-in-Class Programs Targeting Type 2 Angiotensin II Receptor (AGTR2) for PCOS
7.8 First-in-Class Programs Targeting Neuromedin K Receptor (TACR3) for PCOS, Endometriosis, Uterine Fibroids and Vasomotor Symptoms of Menopause
7.9 First-in-Class Programs Targeting Eukaryotic Translation Initiation Factor 2 Alpha Kinase 3 (EIF2AK3) for CIN
7.10 First-in-Class Programs Targeting Human Papillomavirus Protein E6 (E6) and Human Papillomavirus Protein E7 for CIN

8 Strategic Consolidations
8.1 First-in-Class Products with and without Prior Deal Involvement in Licensing and Co-development Deals
8.1.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.2.1 Deals by Region, Value and Year
8.2.2 Deals by Stage of Development and Value
8.2.3 Deals by Molecule Type, Molecular Target and Value
8.2.4 List of Deals with Disclosed Deal Values
8.3 Co-Development Deals
8.3.1 Deals by Region, Value and Year
8.3.2 Deals by Stage of Development and Molecule Type
8.3.3 Deals by Molecule Type, Molecular Target and Aggregate Deal value
8.3.4 List of Deals with Disclosed Deal Values
8.4 First-in-Class Programs with and without Prior Deal Involvement

9 Appendix
9.1 References
9.2 Abbreviations
9.3 Pipeline Disease List
9.4 Research Methodology
9.4.1 Data integrity
9.4.2 Innovative and meaningful analytical techniques and frameworks
9.4.3 Evidence based analysis and insight
9.5 Secondary Research
9.5.1 Market Analysis
9.5.2 Pipeline Analysis
9.5.3 Licensing and Co-development Deals
9.6 Contact
9.7 Disclaimer

List of Tables
Table 1: Women’s Health, Global, Classification of CIN, 2018
Table 2: Women’s Health, Global, PCOS Diagnostic Criteria for NIH, Rotterdam and AE-PCOS Classification Systems, 2018
Table 3: Women’s Health, Global, Types of Female Contraceptives, 2018
Table 4: Women’s Health, Global, Key Details of Prostaglandin E2 Receptor EP4 Subtype (PTGER4), 2018
Table 5: Women’s Health, Global, Pipeline Programs Targeting Prostaglandin E2 Receptor EP4 Subtype (PTGER4), 2018
Table 6: Women’s Health, Global, Key Details of Patatin-Like Phospholipase Domain Containing Protein 2 (PNPLA2), 2018
Table 7: Women’s Health, Global, Women’s Health, Global, Pipeline Programs Patatin-like Phospholipase Domain Containing Protein 2 (PNPLA2), 2018
Table 8: Women’s Health, Global, Key Details of Glutamyl Aminopeptidase (ENPEP), 2018
Table 9: Women’s Health, Global, Pipeline Programs Targeting Glutamyl Aminopeptidase (ENPEP), 2018
Table 10: Women’s Health, Global, Key Details of Prostaglandin E synthase (PTGES), 2018
Table 11: Women’s Health, Global, Pipeline Programs Targeting Prostaglandin E synthase (PTGES), 2018

List of Figures
Figure 1: Women’s Health, US, Innovation Trends in Product Approvals, 1987-2014
Figure 2: Women’s Health, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013
Figure 3: Women’s Health, Global, Market by Molecule Type, 2018
Figure 4: Women’s Health, Global, Market by Molecular Target, 2018
Figure 5: Women’s Health, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
Figure 6: Women’s Health, Global, Pipeline by Stage of Development and Molecule Type, 2018
Figure 7: Women’s Health, Global, Key Indications by Stage of Development, 2018
Figure 8: Women’s Health, Global, Key Indications by Molecule Type, 2018
Figure 9: Women’s Health, Global, Pipeline by Molecular Target, 2018
Figure 10: Women’s Health, Global, Breakdown of Key Molecular Target Classes, 2018
Figure 11: Women’s Health, Global, Key Indications by Molecular Target Class, 2018
Figure 12: Women’s Health, Global, Pipeline and Marketed Products by Molecular Target Class, 2018
Figure 13: Women’s Health, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2018
Figure 14: Women’s Health, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2018
Figure 15: Women’s Health, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2018
Figure 16: Women’s Health, Global, List of All Pipeline Products, 2018 (part 1)
Figure 17: Women’s Health, Global, List of All Pipeline Products, 2018 (part 2)
Figure 18: Women’s Health, Global, List of All Pipeline Products, 2018 (part 3)
Figure 19: Women’s Health, Global, List of All Pipeline Products, 2018 (part 4)
Figure 20: Women’s Health, Global, List of All Pipeline Products, 2018 (part 5)
Figure 21: Women’s Health, Global, List of All Pipeline Products, 2018 (part 6)
Figure 22: Women’s Health, Global, List of All Pipeline Products, 2018 (part 7)
Figure 23: Women’s Health, Global, List of All Pipeline Products, 2018 (part 8)
Figure 24: Women’s Health, Global, List of All Pipeline Products, 2018 (part 9)
Figure 25: Women’s Health, Global, List of All Pipeline Products, 2018 (part 10)
Figure 26: Women’s Health, Global, First-in-Class Matrix Assessment for Endometriosis, 2018
Figure 27: Women’s Health, Global, First-in-Class Matrix Assessment for PCOS, 2018
Figure 28: Women’s Health, Global, First-in-Class Matrix Assessment for CIN (Human Proteins), 2018
Figure 29: Women’s Health, Global, First-in-Class Matrix Assessment for CIN (Viral Proteins), 2018
Figure 30: Women’s Health, Global, All First-in-Class Molecular Targets Across the Women’s Health Pipeline, 2018
Figure 31: Women’s Health, Global, Industry-Wide Licensing Deals by Stage of Development and First-in-Class Product Status, 2006-2015
Figure 32: Women’s Health, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Product Status ($m), 2006-2015
Figure 33: Women’s Health, Global, Licensing Deals by Region, Value and Year, 2018
Figure 34: Women’s Health, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2018
Figure 35: Women’s Health, Global, Licensing Deals by Molecule Type, Molecular Target and Aggregate Deal Value, 2018
Figure 36: Women’s Health, Global, Licensing Deals with Disclosed Deal Values, 2018 (part 1)
Figure 37: Women’s Health, Global, Licensing Deals with Disclosed Deal Values, 2018 (part 2)
Figure 38: Women’s Health, Global, Co-development Deals by Region, Value and Year, 2018
Figure 39: Women’s Health, Global, Licensing Deals by Region, Value and Year, 2018
Figure 40: Women’s Health, Global, Licensing Deals by Region, Value and Year, 2018
Figure 41: Women’s Health, Global, Co-development with Disclosed Deal Values, 2018
Figure 42: Women’s Health, Global, First-in-Class Products with and without Prior Involvement in Licensing and Co-development Deals, 2018 (part 1)
Figure 43: Women’s Health, Global, First-in-Class Products with and without Prior Involvement in Licensing and Co-development Deals, 2018 (part 2)

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll